# PHAR 7484 Integrated Pharmacy 4 (PTX-4): GI, Nutrition, Musculoskeletal Spring Semester 2021

# **Course Description**

This integrated pharmacy course focuses on pathophysiology, medicinal chemistry, pharmacology, and therapeutics to develop therapeutic plans for patients with gastrointestinal, nutritional, and musculoskeletal disorders.

#### **Additional Course Information**

This course introduces basic science and clinical concepts of pharmacy practice. The focus of this course surrounds scientific and therapeutic aspects of the gastrointestinal and musculoskeletal systems and common diseases affecting those systems. In addition, this course will focus on how to appropriately address nutritional disorders. Development of patient-specific therapeutic plans using non-prescription, non-pharmacological, complementary and prescription modalities will be learned. Ultimately, students will be provided with the knowledge-base and clinical skills necessary to provide pharmaceutical care to patients with gastrointestinal and musculoskeletal disorders.

Course Credit: 4 credit hours

Pre-Requisites: P2 Standing

Co-Requisites: None

### **Class Meeting Days, Time & Location**

Tuesday 3:00 – 5:00PM, W.T. Brookshire Hall Room 136 and 137 Friday 1:00 – 3:00PM, W.T. Brookshire Hall Room 136 and 137

# **Course Coordinator**

Shannon D. Rice, Pharm.D., BCGP W.T. Brookshire Hall Room 256 Phone number: 903.565.6437 Email: srice@uttyler.edu

Office hours: TBD (see Canvas course site)
Preferred method of contact: Email

# Fisch College of Pharmacy (FCOP) and UT Tyler Policies

This is part 1 of the syllabus. Part 2 contains UT Tyler and the FCOP course policies and procedures. These are available as a PDF at <a href="https://www.uttyler.edu/pharmacy/academic-affairs/files/fcop-syllabus-policies.pdf">https://www.uttyler.edu/pharmacy/academic-affairs/files/fcop-syllabus-policies.pdf</a>. Syllabus Part 3 contains specific-policies adapted regarding instruction during COVID. For experiential courses (i.e., IPPE and/or APPE), the Experiential Manual contains additional policies and instructions that supplement the Syllabus Part 1 and 2. Please note, the experiential manual may contain policies with different deadlines and/or instructions. The manual should be followed in these cases.

Syllabus Template Revised 10/14/2020 Page 1 of 5

# **Required Materials**

Most course required materials are available through the Robert R. Muntz Library. These materials are available either online\* (<a href="http://library.uttyler.edu/">http://library.uttyler.edu/</a>) or on reserve.

- 1. Pharmacotherapy: A Pathophysiologic Approach, 10th Edition. DiPiro JT, Talbert RL, Yee GC, et al. McGraw-Hill Education. (©2017) ISBN 978-1-259-58748-1
- 2. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy Fourth Edition, 4<sup>th</sup> Edition. Golan DE, Armstrong EJ, Armstrong AW. Wolters Kluwer. (©2017) ISBN 9781451191004
- 3. Other required materials will be posted on the classes' Canvas site: uttyler.edu/canvas.

#### Recommended Materials: None

#### **Course Format**

The course may include, but is not limited to, the following activities:

- 1. Independent study of selected readings
- 2. Individual readiness assessment tests (iRATs)
- 3. Team-based learning, active learning strategies:
  - a. Team readiness assessments (tRAT)
  - b. Team application of content and concepts
  - c. Team presentation of content and concepts
  - d. Team project(s)
  - e. SOAP note(s)
- 4. Independent preparation of reflection papers or other assignments

# **Course Learning Outcomes (CLOs)**

| CLOs  | PLO(s) Assessed for this CLO | EPAs                            | Assessment<br>Methods | Grading<br>Method | PPCP<br>Skill(s)<br>Assessed | ACPE<br>Std.<br>11 &<br>12 |
|---|------------------------------|---------------------------------|-----------------------|-------------------|------------------------------|----------------------------|
| 1. Select appropriate medication therapy for gastrointestinal and musculoskeletal conditions based on principles of physiology, pathophysiology and pharmacology. | 1, 2                         | 1.1<br>1.2                      | 1, 2                  | ES                | 1, 2, 3                      | 4                          |
| Formulate patient-and disease-specific care plans for pharmacotherapeutic regimens in gastrointestinal and musculoskeletal disorders.                             | 1, 2, 4                      | 1.1<br>1.2<br>1.3<br>1.4<br>4.2 | 1, 2                  | ES                | 1, 2, 3, 4                   | 4                          |
| 3. Design monitoring plans for efficacy, toxicity and adverse effects for pharmacotherapeutic regimens in renal and respiratory disorders.                        | 1, 2, 6                      | 1.5<br>3.2                      | 1, 2                  | ES                | 3, 4, 5                      | 4                          |
| 4. Discuss parenteral and enteral nutrition.  | 1, 2, 9                      | 1.1<br>1.2<br>1.3<br>1.4<br>1.5 | 1, 2                  | ES                | 1, 2, 3, 4,<br>5             | 4                          |

Syllabus Template Revised 10/14/2020 Page 2 of 5

#### **Course Assessment Methods**

|   | Assessment Method  | Description  Please provide a brief description of each summative assessment that  you plan to use in this course to allow us to identify which ACPE  standards are being assessed |
|---|--|--|
| 1 | Final Exam Multiple Choice or Multiple Selection Question(s) | Standard MCQ and Select All that apply questions.  |
| 2 | Final Exam Open Ended Question(s)                            | Handwritten calculations, FITB, short answer   |

#### **Grading Policy & Grade Calculation**

Grades will be determined based on evaluation of individual and team readiness assessment tests (iRATs, tRATs), individual and team cumulative assessment tests (iCATs, tCATs), midterm examinations, final written examinations, skills assessments, graded application assignments, participation in team-based projects, peer evaluations and other assessment methods that may include, but not limited to, Objective Structured Clinical Examinations (OSCE). Examinations, RATs and CATs may consist of, but not limited to, multiple-choice, true/false, fill in the blank, shortanswer, essay, and problem-based questions.

During the time the course is in progress, students whose cumulative course percentage falls below 70.0% may receive an academic alert and be subject to periodic course content review in special sessions with the course instructor(s). The student's faculty advisor may receive an academic alert to act upon on the student's behalf.

All examinations, tests, and assignments, including the final examination, may be **cumulative**. Students are responsible for material presented during the prior courses. The grading scale for all graded material is below. The final course grade will be assigned according to the calculated percentage and the percentages will not be rounded upward or downward. For additional information, see examination/assessment policy below.

| Standard Grade Calculation*       |      |  |  |
|-----------------------------------|------|--|--|
| Individual Component              | 95%  |  |  |
| iRATs                             | 15%  |  |  |
| Midterm 1                         | 25%  |  |  |
| Midterm 2                         | 25%  |  |  |
| Final Exam                        | 30%  |  |  |
| Team Component                    |      |  |  |
| tRATs                             | 2.5% |  |  |
| Team Application(s)/Team Projects | 2.5% |  |  |
| Total                             | 100% |  |  |

#### \*The final course letter arade will be determined accordina to the followina aradina scheme:

| The final course letter grade will be determined according to the following grading scheme. |                 |  |  |
|---|-----------------|--|--|
| А   | 90 - 100 %      |  |  |
| В   | 80 - 89.999 %   |  |  |
| С   | 70 - 79.999 %   |  |  |
| D   | 65.0 - 69.999 % |  |  |
| F   | < 65.0 %        |  |  |

Syllabus Template Revised 10/14/2020 Page 3 of 5

# **PHAR 7484 Course Schedule**

| Day       | Торіс  | Instructor    | CLO     | Disease States                |
|-----------|--|---------------|---------|-------------------------------|
| 1/11-1/15 | Clinical Evaluation of the Gastrointestinal Tract *  | Dunn - Online |         | S03.13                        |
| 1/12      | Physiology & Pharmacology: Gastrointestinal Review and Disorders of Gastric Acid *   | Wang          | 1, 2    | \$03.13                       |
| 1/15      | Pathophysiology & Pharmacology: Nausea & Vomiting *  | Wang          | 1, 2    | \$03.01<br>\$03.02<br>\$03.09 |
| 1/19      | Pharmacotherapy: Nausea and Vomiting *   | Rice          | 1, 2, 3 | \$03.09                       |
| 1/22      | Pharmacotherapy: GERD, Dyspepsia, Heartburn *  | Rice          | 1, 2, 3 | S03.01                        |
| 1/26      | Pharmacotherapy: GERD, Dyspepsia, Heartburn  | Rice          | 1, 2, 3 | S03.01                        |
| 1/29      | Pharmacotherapy: Peptic Ulcer Disease *  | Rice          | 1, 2, 3 | S03.02                        |
| 2/2       | Pharmacotherapy: Gastrointestinal Bleeding *   | Dunn          | 1, 2, 3 | S03.13                        |
| 2/5       | Midterm Exam 1 - Covers material 1/11 through 2/2  |               |         |                               |
| 2/9       | Pathophysiology & Pharmacology: Diarrhea, Constipation, IBS (i.e. disorders of gastrointestinal motility and water flux) * | Wang          | 1, 2    | S03.07<br>S03.08<br>S03.10    |
| 2/12      | Pharmacotherapy: Diarrhea & Constipation *   | Yett          | 1,2, 3  | S03.07<br>S03.08              |
| 2/16      | Pharmacotherapy: Irritable Bowel Syndrome *  | Yett          | 1,2, 3  | S03.10                        |
| 2/19      | Pharmacotherapy & Communication: Cirrhosis *   | Dunn          | 1, 2, 3 | S03.04                        |
| 2/23      | Pharmacotherapy & Communication: Cirrhosis   | Dunn          | 1, 2, 3 | S03.04                        |
| 2/26      | Pharmacotherapy: Drug-Induced Liver Disease *  | Rice          | 1, 2, 3 | S03.05                        |
| 3/2       | Pharmacotherapy: Malabsorptive Syndrome *  | Romerill      | 4       | S03.13<br>S17.05              |
| 3/5       | Pharmacotherapy: Parenteral Nutrition *  | Romerill      | 4       | S03.13<br>S17.01              |
| 3/16      | Pharmacotherapy: Enteral Nutrition *   | Romerill      | 4       | S03.13<br>S17.02              |
| 3/19      | Pharmacotherapy: Pancreatitis *  | Rice          | 1, 2, 3 | S03.11                        |
| 3/23      | Midterm Exam 2 - Covers material 2/9 through 3/19  |               |         |                               |

| Day           | Topic  | Instructor | CLO     | Disease States |
|---------------|--|------------|---------|----------------|
| 3/26          | Pathophysiology & Pharmacology: Inflammation, Autoimmunity, Immunosuppression and Pain * | Pearson    | 1, 2    | S03.03         |
|               |  |            |         | S10.01         |
|               |  |            |         | S10.06         |
|               |  |            |         | S11.01         |
|               |  |            |         | S11.02         |
|               |  |            |         | S11.03         |
| 3/30          | Pathophysiology & Pharmacology: Inflammation, Autoimmunity, Immunosuppression and Pain   | Pearson    | 1, 2    | S03.03         |
|               |  |            |         | S10.01         |
|               |  |            |         | S10.06         |
|               |  |            |         | S11.01         |
|               |  |            |         | S11.02         |
|               |  |            |         | S11.03         |
| 4/2           | Pharmacotherapy: Inflammatory Bowel Disease *  | Newsome    | 1, 2, 3 | S03.03         |
| 4/6           | Pharmacotherapy: Inflammatory Bowel Disease  | Newsome    | 1, 2, 3 | S03.03         |
| 4/9           | Pharmacotherapy: Systemic Lupus Erythematosus *  | Newsome    | 1, 2, 3 | S10.01         |
| 4/13          | Pharmacotherapy: Systemic Lupus Erythematosus  | Newsome    | 1, 2, 3 | S10.01         |
| 4/16          | Pharmacotherapy: Rheumatoid Arthritis *  | Newsome    | 1, 2, 3 | S11.01         |
| 4/20          | Pharmacotherapy: Gout *  | Rice       | 1, 2, 3 | S11.03         |
| 4/23          | Pharmacotherapy: Osteoarthritis *  | Bratteli   | 1, 2, 3 | S11.02         |
| TBD           | Cumulative Final Exam (+ new material 3/25 through 4/23)                                 |            |         |                |
| *Indicates in | itended dates of iRATs   | <u> </u>   |         |                |